Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000142

Drug Information
Synonyms1-[bis(4-fluorophenyl)methyl]-4-[(E)-3-phenylprop-2-enyl]piperazine; BPBio1_000336; DB04841; 30484-77-6 (di-hydrochloride); CID941361; Flunarizin; Novo-Flunarizine; HMS1989D03; Flunarizine (INN); CHEMBL30008; BRD-K12184470-300-01-8; 40218-96-0; Sibelium; HMS2089H21; HMS1791D03; Vertix; AC1LIZWP; NCGC00024308-06; D07971; NCGC00018102-09; NCGC00024308-04; Issium; NCGC00024308-07; AR-1B9446; EINECS 254-842-0; Spectrum5_001570; Apo-flunarizine capsules; Flunarizine [INN:BAN]; BRD-K29582677-001-02-7; Zinasen; 1-(Bis(4-fluorophenyl)methyl)-4-cinnamylpiperazine; EINECS 257-937-5; Flunarizinum; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-; HMS1361D03; LS-110464; BCBcMAP01_000120; BSPBio_000304; Lopac0_000527; NCGC00024308-05; Flunarizina [INN-Spanish]; CHEBI:138764; IDI1_000043; flunarizine; BRD-K29582677-300-05-6; Fluvert; Bio-0741; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-, (E)-; MolPort-000-732-712; 52468-60-7; 5343-57-7; Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[(2E)-3-phenyl-2-propenyl]-; AC1Q4NMD; Sibelium (TN); AC-1283; (E)-1-(Bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)piperazine; C26H26F2N2; KST-1B4966; Flunarizinum [INN-Latin]; R-14950; 1-[bis(4-fluorophenyl)methyl]-4-(3-phenylprop-2-en-1-yl)piperazine; Prestwick2_000312; BSPBio_003096; (E)-1-[Bis-(p-fluorophenyl)methyl]-4-cinnamylpiperazine; Flunarizina; Piperazine, 1-(bis(4-fluorophenyl)methyl)-4-(3-phenyl-2-propenyl)-, (E)-; IDI1_033811; Flufenal; BSPBio_001341; Prestwick3_000312    
Trade NameSibelium    
CompanyJanssen Pharmaceutica    
IndicationMigraineApproved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Therapeutic ClassAnticonvulsants    
CAS NumberCAS 52468-60-7
PubChem Compound IDCID 941361.    
PubChem Substance IDSID 181267.    
SuperDrug ATC IDN07CA03;    
SuperDrug CAS ID052468607;    
TargetVoltage-dependent T-type calcium channelBlocker[2][3]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012102 To Reference
Ref 2Positive Allosteric Interaction of Structurally Diverse T-Type Calcium Channel Antagonists. Cell Biochem Biophys. 2009 Jul 7. [Epub ahead of print] To Reference
Ref 3Migraine prophylaxis with calcium antagonists: a haemodynamic study using transcranial Doppler ultrasound. Rev Neurol. 2004 Feb 16-29;38(4):316-9. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543